Enhanced Predictive Capability of a 1-Hour Oral Glucose Tolerance Test: A Prospective Population-Based Cohort Study
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine whether the 1-h blood glucose measurement would be a more suitable screening tool for assessing the risk of diabetes and its complications than the 2-h measurement. RESEARCH DESIGN AND METHODS: We conducted a prospective population-based cohort study of 4,867 men, randomly selected from prespecified birth cohorts between 1921 and 1949, who underwent an oral glucose tolerance test with blood glucose measurements at 0, 1, and 2 h. Subjects were followed for up to 39 years, with registry-based recording of events. Discriminative abilities of elevated 1-h (≥8.6 mmol/L) versus 2-h (≥7.8 mmol/L) glucose for predicting incident type 2 diabetes, vascular complications, and mortality were compared using Kaplan-Meier analysis, Cox proportional hazards regression, and net reclassification improvement. RESULTS: Median age was 48 years (interquartile range [IQR] 48–49). During follow-up (median 33 years [IQR 24–37]), 636 (13%) developed type 2 diabetes. Elevated 1-h glucose was associated with incident diabetes (hazard ratio 3.40 [95% CI 2.90–3.98], P < 0.001) and provided better risk assessment than impaired glucose tolerance (Harrell concordance index 0.637 vs. 0.511, P < 0.001). Addition of a 1-h measurement in subjects stratified by fasting glucose provided greater net reclassification improvement than the addition of a 2-h measurement (0.214 vs. 0.016, respectively). Finally, the 1-h glucose was significantly associated with vascular complications and mortality. CONCLUSIONS: The 1-h blood glucose level is a stronger predictor of future type 2 diabetes than the 2-h level and is associated with diabetes complications and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055 · cited 1×
“Reported validities in the Swedish National Inpatient Register were high for all diagnoses (26).”
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092
Self-citationCavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501
Self-citationWhat is the best predictor of future type 2 diabetes
Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A., & Stern, M. (2007) · Diabetes Care · doi:10.2337/dc06-1331 · Cited by 355
Saito, T. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.275 · Cited by 277
Screening for Diabetes and Pre-Diabetes With Proposed A1C-Based Diagnostic Criteria
Olson, D. E., Rhee, M. K., Herrick, K., Ziemer, D. C., Twombly, J. G., & Phillips, L. S. (2010) · Diabetes Care · doi:10.2337/dc10-0433 · Cited by 255
Eriksson, K.-F., & Lindg�rde, F. (1998) · Diabetologia · doi:10.1007/s001250051024 · Cited by 184 · cited 1×
“39 years 636 (13) 259 (8) 343 (22) 4 (13) 30 (23)”
Self-citationFiorentino, T. V., Marini, M. A., Andreozzi, F., Arturi, F., Succurro, E., Perticone, M., Sciacqua, A., Hribal, M. L., Perticone, F., & Sesti, G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2573 · Cited by 138
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Hulman, A., Witte, D. R., Vistisen, D., Balkau, B., Dekker, J. M., Herder, C., Hatunic, M., Konrad, T., Færch, K., & Manco, M. (2018) · Diabetes Care · doi:10.2337/dc18-0279 · Cited by 66
Lechner, K., Lechner, B., Crispin, A., Schwarz, P. E. H., & von Bibra, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87266-z · Cited by 46
Metadata
- Authors
- Pareek, M., Bhatt, D. L., Nielsen, M. L., Jagannathan, R., Eriksson, K.-F., Nilsson, P. M., Bergman, M., & Olsen, M. H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-11-14
- Volume
- 41
- Issue
- 1
- Pages
- 171-177
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2768354194
- Cited by
- 140
- References
- 15
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.